Janus Henderson Group’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-6,280,305
| Closed | -$298M | – | 2407 |
|
|
2025
Q3 | $298M | Sell |
6,280,305
-458,251
| -7% | -$22.2M | 0.14% | 145 |
|
|
2025
Q2 | $360M | Sell |
6,738,556
-330,092
| -5% | -$15M | 0.18% | 125 |
|
|
2025
Q1 | $302M | Buy |
7,068,648
+1,034,409
| +17% | +$43.8M | 0.17% | 142 |
|
|
2024
Q4 | $168M | Sell |
6,034,239
-1,043,239
| -15% | -$31.6M | 0.09% | 211 |
|
|
2024
Q3 | $203M | Buy |
7,077,478
+201,225
| +3% | +$5.25M | 0.1% | 189 |
|
|
2024
Q2 | $161M | Buy |
6,876,253
+754,283
| +12% | +$16.1M | 0.09% | 201 |
|
|
2024
Q1 | $155M | Buy |
6,121,970
+1,815,569
| +42% | +$43.6M | 0.08% | 211 |
|
|
2023
Q4 | $101M | Sell |
4,306,401
-180,325
| -4% | -$3.56M | 0.06% | 250 |
|
|
2023
Q3 | $227M | Buy |
4,486,726
+61,607
| +1% | +$2.87M | 0.15% | 154 |
|
|
2023
Q2 | $207M | Buy |
4,425,119
+613,443
| +16% | +$28.1M | 0.13% | 162 |
|
|
2023
Q1 | $146M | Buy |
3,811,676
+471,502
| +14% | +$21M | 0.1% | 201 |
|
|
2022
Q4 | $183M | Sell |
3,340,174
-5,210,744
| -61% | -$223M | 0.13% | 172 |
|
|
2022
Q3 | $291M | Buy |
8,550,918
+5,482,606
| +179% | +$83.9M | 0.11% | 196 |
|
|
2022
Q2 | $29M | Sell |
3,068,312
-300,350
| -9% | -$3.13M | 0.02% | 506 |
|
|
2022
Q1 | $47.8M | Buy |
3,368,662
+205,040
| +6% | +$3.59M | 0.02% | 512 |
|
|
2021
Q4 | $66.9M | Sell |
3,163,622
-71,365
| -2% | -$1.58M | 0.03% | 459 |
|
|
2021
Q3 | $72.3M | Sell |
3,234,987
-252,508
| -7% | -$5.72M | 0.03% | 449 |
|
|
2021
Q2 | $86.5M | Buy |
3,487,495
+4,830
| +0.1% | +$136K | 0.04% | 420 |
|
|
2021
Q1 | $101M | Sell |
3,482,665
-10,754
| -0.3% | -$326K | 0.05% | 368 |
|
|
2020
Q4 | $90.1M | Sell |
3,493,419
-42,036
| -1% | -$1.17M | 0.04% | 389 |
|
|
2020
Q3 | $109M | Buy |
3,535,455
+796,937
| +29% | +$27.9M | 0.06% | 307 |
|
|
2020
Q2 | $68.2M | Sell |
2,738,518
-28,302
| -1% | -$647K | 0.04% | 412 |
|
|
2020
Q1 | $58.7M | Buy |
2,766,820
+357,287
| +15% | +$7.66M | 0.04% | 415 |
|
|
2019
Q4 | $53.5M | Buy |
2,409,533
+379,505
| +19% | +$7.85M | 0.03% | 567 |
|
|
2019
Q3 | $44.6M | Buy |
2,030,028
+1,268,875
| +167% | +$29.5M | 0.02% | 610 |
|
|
2019
Q2 | $14.6M | Buy |
+761,153
| New | +$14.4M | 0.01% | 865 |
|
Other funds holding AKRO
Janus Henderson Group's AKRO Position: Q4 2025 in Review
Janus Henderson Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,280,305 shares — an estimated $298M sold.
Janus Henderson Group first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $360M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Janus Henderson Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Janus Henderson Group sold 6,280,305 Akero Therapeutics shares in Q4 2025, an estimated $298M.
- Janus Henderson Group first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- Janus Henderson Group's Akero Therapeutics position peaked at $360M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Janus Henderson Group's 13F filing for Q4 2025, filed 17 Feb 2026.